Shilpa Medicare launches first branded generic anticancer drug ‘Dasashil'

24 Apr 2020 Evaluate

Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anticancer drug with a brand name ‘Dasashil’. Dasashil is first branded generic anticancer drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML). Current, monthly therapy cost of innovator is approximately 1.65 lakh, with the launch of Dasashil monthly cost of treatment will be reduced drastically to Rs 6440 as monthly therapy cost.

Dasahil will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability. The products are being manufactured and supplied from the state-of-the-art US Food and Drug Administration (US FDA) approved manufacturing facility.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

324.55 3.65 (1.14%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×